Buscar
Mostrando ítems 1-2 de 2
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...
Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial
(American Medical Association, 2021-10-13)
[Abstract] Importance: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant ...